Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide VAC Alternating with Vincristine and Irinotecan VI versus VAC/VI plus Temsirolimus TORI, Torisel, NSC 683864 in Patients with Intermediate Risk IR Rhabdomyosarcoma RMS
Study Type: Treatment
Phase: III
NCTID: NCT02567435
Principal Investigator:
Keith August
A Phase IB Trial of Neoadjuvant AMG 232 Concurrent With Preoperative Radiotherapy in Wild-Type p53 Soft Tissue Sarcoma STS
Study Type: Treatment
Phase: I
NCTID: NCT03217266
Principal Investigator:
Benjamin Powers
A Randomized Phase III Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide VINO-AC Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide VINO-CPO vs Vincristine, Dactinomycin and Cyclophosphamide VAC plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma HR-RMS
Study Type: Treatment
Phase: III
NCTID: NCT04994132
Principal Investigator:
Keith August
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Study Type: Prevention
Phase: III
NCTID: NCT02851407
Principal Investigator:
Rakesh Goyal
Phase II Trial of XL184 Cabozantinib an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Study Type: Treatment
Phase: II
NCTID: NCT02867592
Principal Investigator:
Kevin Ginn
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Tenosynovial Giant Cell Tumour
Study Type: Treatment
Phase: III
NCTID: NCT05417789
Principal Investigator:
Benjamin Powers
Biospecimen Analysis in Determining Effects of Chemotherapy on Fertility in Osteosarcoma Survivors
Study Type: Other
Phase: N/A
NCTID: NCT03206450
Principal Investigator:
Keith August
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial
Study Type: Treatment
Phase: III
NCTID: NCT03295981
Principal Investigator:
Kyle Sweeney
A Prospective Phase III Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Study Type: Treatment
Phase: III
NCTID: NCT05304585
Principal Investigator:
Keith August
Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin BI 907828 treatment in patients with treatment-na�ve or pre-treated advanced dedifferentiated liposarcoma
Study Type: Treatment
Phase: III
NCTID: NCT06058793
Principal Investigator:
Benjamin Powers